

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/375,609	08/17/1999	LAWRENCE A. RHEINS	09373/002001	5338
7:	590 02/11/2002			
LISA A. HAILE GRAY CARY WARE & FRIEDENRICH 4365 EXECUTIVE DRIVE SUITE 1600 SAN DIEGO, CA 92121			EXAMINER	
			PRASAD, SARADA C	
			ART UNIT	PAPER NUMBER
			1646	
			DATE MAILED: 02/11/2002	


Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Application No. Og/375,609 Examiner Sarada C Prasad THE REPLY FILED 10 January 2002 FAILS TO PLACE THIS APPLICATION IN CONDITION FOR ALLOWANCE. Therefore, further action by the applicant is required to avoid abandonment of this application. A proper reply to a final rejection under 37 CFR 1.113 may only be either: (1) a timely filed amendment which places the application in condition for allowance; (2) a timely filed Notice of Appeal (with appeal fee); or (3) a timely filed Request for Continued Examination (RCF) in compliance with 37 CFR 1.114.

Examination (RCE) in compliance with 37 CFR 1.114. PERIOD FOR REPLY [check either a) or b)] a) \square The period for reply expires $\underline{4}$ months from the mailing date of the final rejection. The period for reply expires on: (1) the mailing date of this Advisory Action, or (2) the date set forth in the final rejection, whichever is later. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of the final rejection. ONLY CHECK THIS BOX WHEN THE FIRST REPLY WAS FILED WITHIN TWO MONTHS OF THE FINAL REJECTION. See MPEP Extensions of time may be obtained under 37 CFR 1.136(a). The date on which the petition under 37 CFR 1.136(a) and the appropriate extension fee have been filed is the date for purposes of determining the period of extension and the corresponding amount of the fee. The appropriate extension fee under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the shortened statutory period for reply originally set in the final Office action; or (2) as set forth in (b) above, if checked. Any reply received by the Office later than three months after the mailing date of the final rejection, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). 1. A Notice of Appeal was filed on ____. Appellant's Brief must be filed within the period set forth in 37 CFR 1.192(a), or any extension thereof (37 CFR 1.191(d)), to avoid dismissal of the appeal. 2. The proposed amendment(s) will not be entered because: (a) ☑ they raise new issues that would require further consideration and/or search (see NOTE below); (b) they raise the issue of new matter (see Note below); (c) X they are not deemed to place the application in better form for appeal by materially reducing or simplifying the issues for appeal; and/or (d) ___ they present additional claims without canceling a corresponding number of finally rejected claims. NOTE: See Continuation Sheet. 3. Applicant's reply has overcome the following rejection(s): _____. 4. Newly proposed or amended claim(s) ____ would be allowable if submitted in a separate, timely filed amendment canceling the non-allowable claim(s). 5. ☑ The a) ☑ affidavit, b) ☐ exhibit, or c) ☐ request for reconsideration has been considered but does NOT place the application in condition for allowance because: see attached. 6. The affidavit or exhibit will NOT be considered because it is not directed SOLELY to issues which were newly raised by the Examiner in the final rejection. 7. ☑ For purposes of Appeal, the proposed amendment(s) a) ☑ will not be entered or b) ☐ will be entered and an explanation of how the new or amended claims would be rejected is provided below or appended. The status of the claim(s) is (or will be) as follows: Claim(s) allowed: _____. Claim(s) objected to: ___ Claim(s) rejected: 64-136. Claim(s) withdrawn from consideration: _____. 8. The proposed drawing correction filed on ____ is a) approved or b) disapproved by the Examiner. 9. Note the attached Information Disclosure Statement(s)(PTO-1449) Paper No(s). _____.

10. Other: ____

Continuation of 2.



Response to Applicants' declaration under 37 C.F.R. 1.132:

The declaration under 37 CFR 1.132 filed in Paper No. 14 (1/10/01) is insufficient to overcome the rejection of claims 64-136 based upon lack of enablement under 35 USC 112-first paragraph as set forth in the last Office action because:

- (i) the data presented in Table 1 in page 3 of Paper No. 14 (1/10/02) is not commensurate with the scope of the claims with regard to detection of IL-4 because the mRNA for IL-4 could not be detected in any samples including the control RNA;
- (ii) it is not clear whether the Ct values are-- an average of the values obtained for the three sites having the same treatment (irritant, vehicle, none), or obtained from three different individuals, or three different sites in the same individual, i.e., how many data points are represented;
- (iii) it is not clear as to how the data in Table 1 showing Ct values representing the number of PCR cycles required to produce a standard reference fluorescence value could have numbers pointing to 1/100th of a cycle.

Advisory Information

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sarada C Prasad whose telephone number is 703-305-1009. The examiner can normally be reached Monday – Friday from 8.00 AM to 4.30 PM (Eastern time). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, can be reached on (703) 308-6564. The fax phone number for the organization where this application or proceeding is assigned is 703-308-0294. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0196.

Sarada Prasad, Ph.D. Examiner Art Unit 1646 January 31, 2002

LORRAINE SPECTOR
PRIMARY EXAMINER